EGFR and malignant peripheral nerve sheath tumor: Our findings not only provide evidence of genetic aberrations of the EGFR signaling pathway in these tumors, but also indicate that genomic amplification and high expression of EGFR are key targetable oncogenic events in MPNST patients.